Related Experiment Video
Updated: Sep 5, 2025
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
MiR-182 antagonist alleviates glucocorticoid-induced secondary bone degeneration and osteoclast differentiation
Bin Zhao1, Min Luo2, Aiyuan Wang3
1Orthopaedic Department of 3rd Medical Center, Chinese PLA General Hospital, Beijing 100039, China. zhaobin202201@163.com.
Abstract:
In this study, the expression of miR-182 in secondary bone degeneration was investigated, and the effect of its antagonist on glucocorticoid-induced osteoclast differentiation and its mechanism was studied. For this purpose, PBMC cell lines were selected for cultivation, and the changes were observed by hematoxylin-eosin (HE) staining. Real-time fluorescence quantitative (qRT-PCR) was used to detect mRNA expression. The protein expressions of RANKL, OPG and CXCL10 were detected by Western blot. CCK-8 and flow cytometry was used to detect cell proliferation and apoptosis. The results showed that protein expression levels of RANKL, OPG and CXCL10 in the miR-182 group were significantly higher than those in other groups (P>0.01). The miR-182 can promote RANK signal transduction in osteoclasts by regulating RANKL/NFκB signaling pathway, accelerating osteoclast proliferation and differentiation, and slowing down the process by miR-182 inhibitor. In general, miR-182 alleviates OP by inhibiting the activity of osteoclast via RANKL/NFκB signaling.
Insights
MicroRNA-182 (miR-182) promotes bone degeneration by enhancing osteoclast activity. Inhibiting miR-182 slows bone loss by reducing osteoclast differentiation and proliferation via the RANKL/NFκB pathway.
Area of Science:
- Molecular Biology
- Cell Biology
- Bone Biology
Background:
- Secondary bone degeneration is a significant health concern.
- Osteoclast differentiation plays a crucial role in bone resorption.
- MicroRNAs are implicated in various cellular processes, including bone metabolism.
Purpose of the Study:
- To investigate the role of miR-182 in secondary bone degeneration.
- To explore the effect of a miR-182 antagonist on glucocorticoid-induced osteoclast differentiation.
- To elucidate the underlying molecular mechanisms.
Main Methods:
- Peripheral blood mononuclear cell (PBMC) culture.
- Hematoxylin-eosin (HE) staining for cell morphology.
- Quantitative real-time PCR (qRT-PCR) for mRNA expression.
- Western blot for protein analysis (RANKL, OPG, CXCL10).
- CCK-8 assay and flow cytometry for cell proliferation and apoptosis.
Main Results:
- miR-182 expression was investigated in the context of bone degeneration.
- Protein levels of RANKL, OPG, and CXCL10 were significantly elevated in the miR-182 group (P>0.01).
- miR-182 promotes osteoclast proliferation and differentiation by regulating the RANKL/NFκB signaling pathway.
Conclusions:
- miR-182 enhances osteoclast differentiation and activity.
- Inhibition of miR-182 can attenuate glucocorticoid-induced bone loss.
- The findings suggest miR-182 as a potential therapeutic target for bone degeneration.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents